A Clinical Study to Investigate the Long-term Use of Lacosamide as Monotherapy in Subjects Who Completed Study SP0994

Phase 3

Completed

• Conditions: Epilepsy
• Interventions: Drug: Lacosamide

• Registration Number: NCT02582866
• Lead Sponsor: UCB Biopharma S.P.R.L.

Brief Summary

Study is conducted to evaluate the long-term safety and tolerability of lacosamide (LCM) in patients receiving LCM in SP0994 \[NCT01465997\]. The study will enable collection of additional monotherapy safety data, and will facilitate access to treatment until commercial availability for monotherapy use.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2015-10-20
• Study First Submitted QC: 2015-10-20
• Study First Posted: 2015-10-21
• Study Start: 2016-01
• Primary Completion: 2020-01
• Study Completion: 2020-01
• Results First Submitted: 2021-01-04
• Results First Submitted QC: 2021-01-04
• Results First Posted: 2021-01-22
• Status Verified: 2023-05
• Last Update Submitted: 2023-05-10
• Last Update Posted: 2023-06-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 106

Inclusion Criteria

• An Institutional Review Board /Institutional Ethics Committee approved written Informed Consent Form (ICF) is signed and dated by the subject or by the parent(s) or legal representative. The ICF or a specific Assent form, where required, will be signed and dated by minors
• Subject/legal representative is considered reliable and capable of adhering to the protocol, visit schedule, and medication intake according to the judgment of the investigator
• Subject has completed the Termination Visit of SP0994 [NCT01465997] and has been treated with lacosamide monotherapy

Exclusion Criteria

• Subject is receiving any investigational drugs or using any experimental devices in addition to lacosamide (LCM)
• Subject experienced a seizure at the 3rd target dose (i.e. LCM 600 mg/day) during SP0994
• Subject required another Anti Epileptic Drug (AED) for the treatment of seizures
• Subject meets a "must" withdrawal criteria for SP0994
• Subject is experiencing an ongoing Serious Adverse Event from SP0994
• Female subject who is pregnant or nursing, and/or a woman of childbearing potential who is not surgically sterile, 2 year postmenopausal or does not practice one highly effective method of contraception, unless sexually abstinent, for the duration of the study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Lacosamide	Lacosamide	Lacosamide (LCM) will be administered orally twice daily from 200 mg/day to 600 mg/day (at approximately 12 hour intervals in the morning and in the evening) in 2 divided doses. Medication must not be chewed and must be swallowed with a sufficient amount of fluid. The investigator may maintain the subject's LCM dose, decrease the dose in decrements of 100 mg/day per week to a minimum dose of LCM 200 mg/day, or increase the dose in increments of 100 mg/day per week up to a maximum dose of LCM 600 mg/day. Subjects stopping LCM should be tapered off LCM at recommended decreasing steps of 200 mg/day/week. A slower taper (eg, 100 mg/day/week) or faster taper is permitted, if medically necessary; however, the maximum duration of tapering should not exceed 6 weeks.

Primary Outcome Measures

Name	Time	Method
Percentage of Participants Experiencing Any Serious Adverse Events (SAEs) Reported Spontaneously by the Subject and/or Caregiver or Observed by Investigator	From Visit 1 (Week 0) to Final Visit (up to Week 158)	A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: * Results in death; * Is life-threatening; * Requires in patient hospitalization or prolongation of existing hospitalization; * Is a congenital anomaly or birth defect; * Is an infection that requires treatment parenteral antibiotics; * Other important medical events which based on medical or scientific judgement may jeopardize the study participants, or may require medical or surgical intervention to prevent any of the above.
Percentage of Participants Experiencing Any Adverse Events (AEs) Reported Spontaneously by the Subject and/or Caregiver or Observed by Investigator	From Visit 1 (Week 0) to Final Visit (up to Week 158)	An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. An AE could, therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study medication.
Percentage of Participants That Withdrew Due to Adverse Events (AEs)	From Visit 1 (Week 0) to Final Visit (up to Week 158)	An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. An AE could, therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study medication.

Trial Locations

Locations (46)

Sp1042 654; 🇨🇭 Biel, Switzerland

Sp1042 625; 🇺🇦 Odesa, Ukraine

Sp1042 340; 🇵🇱 Katowice, Poland

Sp1042 834; 🇯🇵 Kagoshima, Japan

Sp1042 844; 🇯🇵 Kamakura, Japan

Sp1042 837; 🇯🇵 Okayama, Japan

Sp1042 651; 🇨🇭 Aarau, Switzerland

Sp1042 811; 🇧🇬 Sofia, Bulgaria

Sp1042 570; 🇷🇴 Iasi, Romania

Sp1042 805; 🇧🇬 Blagoevgrad, Bulgaria

Sp1042 807; 🇧🇬 Pazardzhik, Bulgaria

Sp1042 835; 🇯🇵 Nagoyashi, Japan

Sp1042 847; 🇯🇵 Sapporo, Japan

Sp1042 751; 🇱🇻 Riga, Latvia

Sp1042 207; 🇫🇮 Kuopio, Finland

Sp1042 831; 🇯🇵 Asaka, Japan

Sp1042 576; 🇷🇴 Bucuresti, Romania

Sp1042 392; 🇷🇺 Novosibirsk, Russian Federation

Sp1042 343; 🇵🇱 Warszawa, Poland

Sp1042 401; 🇷🇺 Moscow, Russian Federation

Sp1042 387; 🇷🇺 Kazan, Russian Federation

Sp1042 626; 🇺🇦 Kharkov, Ukraine

Sp1042 263; 🇩🇪 Altenburg, Germany

Sp1042 236; 🇫🇷 Nancy, France

Sp1042 205; 🇫🇮 Helsinki, Finland

Sp1042 256; 🇩🇪 Marburg, Germany

Sp1042 265; 🇩🇪 Bad Neustadt An Der Saale, Germany

Sp1042 259; 🇩🇪 Osnabruck, Germany

Sp1042 269; 🇩🇪 Leipzig, Germany

Sp1042 521; 🇰🇷 Daegu, Korea, Republic of

Sp1042 518; 🇰🇷 Daejeon, Korea, Republic of

Sp1042 517; 🇰🇷 Seoul, Korea, Republic of

Sp1042 547; 🇲🇽 San Luis Potosi, Mexico

Sp1042 672; 🇵🇭 Pasig, Philippines

Sp1042 676; 🇵🇭 Quezon, Philippines

Sp1042 342; 🇵🇱 Lublin, Poland

Sp1042 572; 🇷🇴 Targu Mures, Romania

Sp1042 389; 🇷🇺 Kazan, Russian Federation

Sp1042 400; 🇷🇺 Saint Petersburg, Russian Federation

Sp1042 397; 🇷🇺 Saint Petersburg, Russian Federation

Sp1042 440; 🇸🇪 Goteborg, Sweden

Sp1042 438; 🇸🇪 Stockholm, Sweden

Sp1042 442; 🇸🇪 Linköping, Sweden

Sp1042 653; 🇨🇭 Lugano, Switzerland

Sp1042 622; 🇺🇦 Chernihiv, Ukraine

Sp1042 519; 🇰🇷 Seoul, Korea, Republic of